Long-term data with idebenone on respiratory function outcomes in patients with Duchenne muscular dystrophy
Decline in respiratory function in patients with DMD starts during early teenage years and leads to early morbidity and mortality. Published evidence of efficacy for idebenone on respiratory function outcomes is currently limited to 12 months of follow-up time. Here we report data collected as retro...
Κύριοι συγγραφείς: | Servais, L, Straathof, CSM, Schara, U, Klein, A, Leinonen, M, Hasham, S, Meier, T, De Waele, L, Gordish-Dressman, H, McDonald, CM, Mayer, OH, Voit, T, Mercuri, E, Buyse, GM |
---|---|
Μορφή: | Journal article |
Γλώσσα: | English |
Έκδοση: |
Elsevier
2019
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy
ανά: Theodora Markati, κ.ά.
Έκδοση: (2021-11-01) -
Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy
ανά: Marshall W. Hogarth, κ.ά.
Έκδοση: (2017-01-01) -
Cholesterol metabolism is a potential therapeutic target in Duchenne muscular dystrophy
ανά: Fatima Amor, κ.ά.
Έκδοση: (2021-06-01) -
Duchenne Muscular Dystrophy
ανά: J Gordon Millichap
Έκδοση: (1989-05-01) -
Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
ανά: Frank, DE, κ.ά.
Έκδοση: (2020)